ZGNX Zogenix Inc

By Colin Kellaher

Zogenix Inc. on Tuesday said it filed with the U.S. Food and Drug Administration for expanded approval of Fintepla for the treatment of seizures associated with Lennox-Gastaut syndrome.

The Emeryville, Calif., pharmaceutical company said the filing is supported by data from a Phase 3 study that showed Fintepla was superior to placebo in reducing the frequency of drop seizures in patients with the severe, rare form of epilepsy that isn't well-controlled by currently available anti-seizure medications.

The FDA last year approved Fintepla for the treatment of seizures associated with Dravet syndrome, a rare childhood-onset epilepsy, in patients two years of age and older.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

September 28, 2021 09:03 ET (13:03 GMT)

Zogenix (NASDAQ:ZGNX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

Zogenix (NASDAQ:ZGNX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024